TY  - GEN
AU  - Simmet,V
AU  - Eberst,L
AU  - Marabelle,A
AU  - Cassier,P A
TI  - Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
SN  - 1569-8041
PY  - 2020///0803
KW  - Antineoplastic Agents, Immunological
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - B7-H1 Antigen
KW  - antagonists & inhibitors
KW  - CTLA-4 Antigen
KW  - Clinical Trials, Phase I as Topic
KW  - standards
KW  - Dose-Response Relationship, Drug
KW  - Humans
KW  - Maximum Tolerated Dose
KW  - Neoplasms
KW  - drug therapy
KW  - Programmed Cell Death 1 Receptor
KW  - Protein Kinase Inhibitors
KW  - Research Design
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Review
UR  - https://doi.org/10.1093/annonc/mdz286
ER  -